Aspen Neuroscience closed a $115 million Series C to advance ANPD001, its autologous iPSC-derived cell therapy for Parkinson’s disease and to scale manufacturing, clinical operations and pipeline expansion. The company highlighted Fast Track designation from the FDA and reported encouraging six‑month safety/efficacy data for early cohorts, signaling investor confidence in personalized regenerative approaches. In the same therapeutics space, Brenig Therapeutics disclosed discovery-stage LRRK2 inhibitors aimed at Parkinson’s patients with LRRK2 mutations. Brenig’s program remains preclinical but supplements the field’s therapeutic diversity by targeting a genetically defined PD subgroup. Together, the financing and discovery work illustrate parallel investment in cell- and small-molecule strategies for Parkinson’s care. Fast Track is a regulatory designation that can speed clinical development and facilitate earlier interactions with the FDA. Investors and developers will watch whether Aspen’s capital accelerates commercial-scale manufacturing — a bottleneck for personalized cell products — and whether Brenig’s inhibitors translate into differentiated clinical candidates.